Pertinencia de las medidas no farmacológicas ante el avance de la vacunación

perspectivas18_molina_alonso

Autores/as

  • Germán Molina Romera Unidad Docente de Medicina Preventiva y Salud Pública de Galicia. Hospital Clínico Universitario de Santiago. Galicia. España.
  • Alfonso Alonso Jaquete Unidad Docente de Medicina Preventiva y Salud Pública de Cantabria. Consejería de Sanidad de Cantabria. Cantabria. España.

Palabras clave:

Medidas no farmacológicas, Vacunas, SARS-CoV-2, COVID-19

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Informe de actividad diario. GIV – Gestión Integral de vacunación frente al COVID-19 en España. Ministerio de Sanidad. Gobierno de España. 26 de mayo de 2021. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Informe_GIV_comunicacion_20210526.pdf

Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev. enero de 2021;65:101205.

Ebrahim S, Ashworth H, Noah C, Kadambi A, Toumi A, Chhatwal J. Reduction of COVID-19 Incidence and Nonpharmacologic Interventions: Analysis Using a US County–Level Policy Data Set. J Med Internet Res. 21 de diciembre de 2020;22(12):e24614.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet. marzo de 2021;397(10277):881-91.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 15 de abril de 2021;384(15):1412-23.

Cabezas C, Coma E, Mora-Fernandez N, Li X, Martinez-Marcos M, Fina-Aviles F et al. Effects of BNT162b2 mRNA Vaccination on COVID-19 Disease, Hospitalisation and Mortality in Nursing Homes and Healthcare Workers: A Prospective Cohort Study Including 28,594 Nursing Home Residents, 26,238 Nursing Home Staff, and 61,951 Healthcare Workers in Catalonia. SSRN Electron J [Internet]. 2021 [citado 27 de mayo de 2021]; Disponible en: https://www.ssrn.com/abstract=3815682

Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet. mayo de 2021;397(10286):1725-35.

Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2 de abril de 2021;70(13):495-500.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 21 de abril de 2021;NEJMoa2101544.

Piubelli C, Deiana M, Pomari E, Silva R, Bisoffi Z, Formenti F et al. Overall decrease in SARS-CoV-2 viral load and reduction in clinical burden: the experience of a hospital in northern Italy. Clin Microbiol Infect. enero de 2021;27(1):131.e1-131.e3.

Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. mayo de 2021;27(5):790-2.

V Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households [Internet]. Public and Global Health; 2021 mar [citado 27 de mayo de 2021]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2021.03.11.21253275

Monge S, Olmedo C, Alejos B, Lapeña MF, Sierra MJ, Limia A et al. Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain [Internet]. Infectious Diseases (except HIV/AIDS); 2021 abr [citado 27 de mayo de 2021]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2021.04.08.21255055

Impact of COVID-19 vaccines on mortality in England December 2020 to February 2021 [Internet]. Public Health England; Disponible en: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972592/COVID-19_vaccine_impact_on_mortality_240321.pdf

Glampson B, Brittain J, Kaura A, Mulla A, Mercuri L, Brett S et al. North West London Covid-19 Vaccination Programme: Real-world evidence for Vaccine uptake and effectiveness [Internet]. Health Informatics; 2021 abr [citado 27 de mayo de 2021]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2021.04.08.21254580

Actualización no 12. Enfermedad por coronavirus (COVID-19) en Centros Residenciales. IMSERSO; 2021. Disponible en: https://www.imserso.es/InterPresent2/groups/imserso/documents/binario/inf_resid_20210516.pdf

Actualización de la situación epidemiológica de las variantes de SARS-CoV-2 de mayor impacto e interés en salud pública en España. Centro de Cordinación de Alertas y Emergencias Sanitarias. Ministerio de Sanidad. Gobierno de España. 24 de mayo de 2021. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Actualizacion_variantes_20210524.pdf

Grint DJ, Wing K, Williamson E, McDonald HI, Bhaskaran K, Evans D et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Eurosurveillance [Internet]. 18 de marzo de 2021 [citado 27 de mayo de 2021];26(11). Disponible en: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.11.2100256

CMMID COVID-19 Working Group, Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 13 de mayo de 2021;593(7858):270-4.

Martins AF, Zavascki AP, Wink PL, Volpato FCZ, Monteiro FL, Rosset C et al. Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil. Eurosurveillance [Internet]. 25 de marzo de 2021 [citado 27 de mayo de 2021];26(12). Disponible en: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.12.2100276

Lindstrøm JC, Engebretsen S, Bråthen Kristoffersen A, Øyvind Isaksson Rø G, Palomares AD-L, Engø-Monsen K et al. Increased transmissibility of the B.1.1.7 SARS-CoV-2 variant: Evidence from contact tracing data in Oslo, January to February 2021 [Internet]. Infectious Diseases (except HIV/AIDS); 2021 mar [citado 27 de mayo de 2021]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2021.03.29.21254122

Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T et al. Changes in symptomatology, re-infection and transmissibility associated with SARS-CoV-2 variant B.1.1.7: an ecological study [Internet]. Epidemiology; 2021 ene [citado 27 de mayo de 2021]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2021.01.28.21250680

Pearson CA, Russell TW. Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa.

Faria NR, Mellan TA, Whittaker C, Claro IM, Candido D da S, Mishra S et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 21 de mayo de 2021;372(6544):815-21.

Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. abril de 2021;184(9):2384-2393.e12.

Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. abril de 2021;29(4):516-521.e3.

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 20 de mayo de 2021;384(20):1899-909.

Edara V-V, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant [Internet]. Immunology; 2021 may [citado 27 de mayo de 2021]. Disponible en: http://biorxiv.org/lookup/doi/10.1101/2021.05.09.443299

Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. octubre de 2020;20(10):583-4.

Soldevilla P, Cardona PJ, Caylà JA, Hernández A, Palma D, Rius C. Revisión sobre las vacunas frente a SARS-CoV-2. Actualización a 31 de enero de 2021. Enf Emerg. 2021;20(1):7-19.

Aguilar L, Chueca I, Costa P, Kolipinski A, Priego F. COVID-19: el impacto de la vacunación en hospitales y UCIs [Internet]. IQVIA; 2021. Disponible en: https://www.iqvia.com/es-es/locations/spain/library/white-papers/covid19-el-impacto-de-la-vacunacion-en-hospitales-y-ucis

Descargas

Publicado

08-06-2021

Cómo citar

1.
Molina Romera G, Alonso Jaquete A. Pertinencia de las medidas no farmacológicas ante el avance de la vacunación: perspectivas18_molina_alonso. Rev Esp Salud Pública [Internet]. 8 de junio de 2021 [citado 15 de noviembre de 2024];95:8 páginas. Disponible en: https://ojs.sanidad.gob.es/index.php/resp/article/view/663

Número

Sección

Perspectivas

Categorías

Artículos más leídos del mismo autor/a